From Dr Eliot Forster, Executive Chair of MedCity
Life sciences investment is the big focus for MedCity this month (and, of course, far beyond), with events and initiatives that mark the start in earnest of our engagement with the financial community on behalf of the sector.
It’s an issue that has been in the air recently. In a rare interview, the renowned fund manager Neil Woodford – a big investor in start ups and pharma – made some helpful comments about the need for investors to take a long-term view. Great news, too, from Adaptimmune, a leading UK biosciences company that recently secured a $104m funding deal – though it had to look to the USA for that investment. We want to get to a stage where the UK is viewed as a natural place for great life sciences companies to grow; this month we lay the groundwork that will get us there.